The first treatment using trastuzumab as IT chemotherapy in HER2-positive breast cancer leptomeningeal carcinomatosis was reported by Laufman and Forsthoefel in 2001 [15] in a 48-year-old woman, with no immediate positive therapeutic effect neither any neurological nor site toxicity. This evidence concerns the gene ERBB2 and breast cancer.